What You Should Know
- The Funding: Verily has closed a $300M investment round led by Series X Capital, a venture fund specifically established to scale Google X “moonshot” technologies into independent companies.
- The Restructuring: The company has officially transitioned its legal structure from an LLC to a corporation, newly named Verily Health Inc.
- Alphabet’s New Role: In a massive corporate shift, Alphabet (Google’s parent company) will remain a “significant minority investor” but will no longer hold a controlling stake in the company it originally spun out a decade ago.
- The Strategic Goal: The $300M will accelerate Verily’s AI-native precision health platform strategy, specifically aimed at helping healthcare organizations harmonize fragmented data and deploy actionable intelligence into clinical workflows.
- The Enterprise Ecosystem: Verily announced major commercial partnerships, including a collaboration with Samsung (using the Galaxy Watch for biomarker development) and Salesforce (integrating the Verily Pre Platform with Agentforce Health).
- The Clinical Partners: The round also included participation from UCHealth and the University of Colorado Anschutz, who are actively using the Verily Pre platform to transform clinical research and care delivery.
The Power of Independence
Why does Alphabet dropping its controlling stake matter? Because in enterprise healthcare, vendor neutrality is everything. When a health IT company is viewed as a pure subsidiary of a Big Tech giant, prospective partners (and competitors of that parent company) are often hesitant to integrate deeply. By establishing true corporate independence, Verily Health Inc. has unlocked the ability to partner freely across the entire tech and medical ecosystem.
We are already seeing this play out in real-time. Alongside the funding, Verily announced major commercial partnerships that cross traditional tech fault lines. They are collaborating with Samsung to utilize the Galaxy Watch for biomarker development in clinical research, and they have struck a strategic partnership with Salesforce to integrate their precision health platform (Verily Pre) directly into Salesforce’s Agentforce Health.
“Today is an important step in our mission to bring the promise of precision health to everyone,” said Stephen Gillett, Chairman and CEO of Verily. “From research to care, our customers need solutions that bring the best of clinical and scientific rigor together with AI to deliver the next generation of healthcare – one that is as precise as it is personal. Series X Capital, Alphabet, UCHealth, the University of Colorado Anschutz and our many investors will be fantastic partners in this transformation of healthcare.”
Scaling the “Moonshot”
The presence of Series X Capital as the lead investor is also highly strategic. Run by former YouTube and Facebook executive Gideon Yu, the fund was explicitly established to act as the “last mile of incubation,” taking the most promising Google X projects and structuring them into financially disciplined, commercially viable standalone enterprises.
With this war chest, Verily is aggressively targeting the most persistent bottleneck in modern medicine: unstructured, siloed data. Health systems are drowning in data but starving for insights. Verily’s AI-native Pre platform is designed to ingest this multimodal health data and output highly personalized, predictive models that clinicians can actually use at the bedside.
“Partnering with Verily to bring a shared data framework to healthcare data, making it AI‑ready, creates a generational opportunity for UCHealth and for medicine,” noted Dr. Richard Zane, Chief Medical and Innovation Officer at UCHealth, which also participated in the funding round.
